Cargando…
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
Renal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor entity by the last World Health Organization classification published in 2016. Although several studies assessing ALK-RCC’s clinical an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999731/ https://www.ncbi.nlm.nih.gov/pubmed/35409355 http://dx.doi.org/10.3390/ijms23073995 |
_version_ | 1784685259788386304 |
---|---|
author | Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Roselli, Mario Torino, Francesco |
author_facet | Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Roselli, Mario Torino, Francesco |
author_sort | Iannantuono, Giovanni Maria |
collection | PubMed |
description | Renal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor entity by the last World Health Organization classification published in 2016. Although several studies assessing ALK-RCC’s clinical and histological characteristics have been published in recent years, only a few publications have evaluated the activity of ALK inhibitors (ALK-i) in this subgroup of patients. Considering the well-recognized efficacy of this evolving class of targeted therapies in other ALK-positive tumors, we conducted a systematic review to evaluate the reported activity of ALK-i in the ALK-RCC subtype. MEDLINE was searched from its inception to 7 January 2022 for case reports and case series on adult metastatic ALK-RCC patients treated with ALK-i whose therapeutic outcomes were available. A virtual cohort of ALK-RCC patients was created. Our results showed a favorable activity of first- and second-generation ALK-i in pretreated ALK-RCC patients in terms of either radiological response or performance status improvement. We hope that the present work will prompt the creation of large, multi-institutional clinical trials to confirm these promising early data. |
format | Online Article Text |
id | pubmed-8999731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89997312022-04-12 Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Roselli, Mario Torino, Francesco Int J Mol Sci Review Renal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor entity by the last World Health Organization classification published in 2016. Although several studies assessing ALK-RCC’s clinical and histological characteristics have been published in recent years, only a few publications have evaluated the activity of ALK inhibitors (ALK-i) in this subgroup of patients. Considering the well-recognized efficacy of this evolving class of targeted therapies in other ALK-positive tumors, we conducted a systematic review to evaluate the reported activity of ALK-i in the ALK-RCC subtype. MEDLINE was searched from its inception to 7 January 2022 for case reports and case series on adult metastatic ALK-RCC patients treated with ALK-i whose therapeutic outcomes were available. A virtual cohort of ALK-RCC patients was created. Our results showed a favorable activity of first- and second-generation ALK-i in pretreated ALK-RCC patients in terms of either radiological response or performance status improvement. We hope that the present work will prompt the creation of large, multi-institutional clinical trials to confirm these promising early data. MDPI 2022-04-03 /pmc/articles/PMC8999731/ /pubmed/35409355 http://dx.doi.org/10.3390/ijms23073995 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Roselli, Mario Torino, Francesco Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review |
title | Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review |
title_full | Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review |
title_fullStr | Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review |
title_full_unstemmed | Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review |
title_short | Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review |
title_sort | activity of alk inhibitors in renal cancer with alk alterations: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999731/ https://www.ncbi.nlm.nih.gov/pubmed/35409355 http://dx.doi.org/10.3390/ijms23073995 |
work_keys_str_mv | AT iannantuonogiovannimaria activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview AT riondinosilvia activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview AT sgangastefano activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview AT rosellimario activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview AT torinofrancesco activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview |